India's Bharat Biotech submits data on COVID-19 drug trial in children

Earlier, the WHO said it will take a call on granting Emergency Use Listing (EUL) status for Bharat Biotech's COVID-19 vaccine Covaxin next week.

  • Updated On Oct 7, 2021 at 04:58 AM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India's drug regulator, becoming the country's first company to have tested its shot in very young children.

The South Asian country is turning its focus towards vaccinating children against the coronavirus, having already administered more than 920 million doses to adults among its population of nearly 1.4 billion.

India's drug regulator last month allowed vaccine maker Serum Institute to enroll kids aged 7 to 11 years for its trial of U.S. drugmaker Novavax's COVID-19 vaccine.

Advt
So far, only drugmaker Zydus Cadila's DNA-based COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged atleast 12 years.
  • Published On Oct 7, 2021 at 04:57 AM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App